Synonym
Spirapril Free Base; Sch33844; Sch-33844; Sch 33844
IUPAC/Chemical Name
(S)-7-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
InChi Key
HRWCVUIFMSZDJS-SZMVWBNQSA-N
InChi Code
InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1
SMILES Code
CCOC([C@@H](N[C@H](C(N1CC2(SCCS2)C[C@H]1C(O)=O)=O)C)CCc3ccccc3)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
466.61
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Noble S, Sorkin EM. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs. 1995 May;49(5):750-66. doi: 10.2165/00003495-199549050-00008. PMID: 7601014.
2: Hayduk K, Kraul H. Efficacy and safety of spirapril in mild-to-moderate hypertension. J Cardiovasc Pharmacol. 1999 Aug;34 Suppl 1:S19-23. doi: 10.1097/00005344-199908001-00004. PMID: 10499560.
3: Hermida RC, Ayala DE, Fontao MJ, Mojón A, Alonso I, Fernández JR. Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension. Chronobiol Int. 2010 May;27(3):560-74. doi: 10.3109/07420528.2010.485411. PMID: 20524801.
4: Guitard C, Lohmann FW, Alfiero R, Ruina M, Alvisi V. Comparison of efficacy of spirapril and enalapril in control of mild-to-moderate hypertension. Cardiovasc Drugs Ther. 1997 Jul;11(3):449-57. doi: 10.1023/a:1007797405850. PMID: 9310273.
5: van den Broek SA, de Graeff PA, Smit AJ, Girbes AR, Journée, van Gilst WH, Hillege H, van Veldhuisen DJ, Wesseling H, Lie KI. Effects of spirapril and captopril on regional blood flow in chronic congestive heart failure: a comparison between a short- and a long-acting angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol. 1995 Jan;25(1):105-12. doi: 10.1097/00005344-199501000-00017. PMID: 7723338.
6: Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. doi: 10.2165/00003088-200241030-00005. PMID: 11929321.
7: Elliot HL. Primenenie ingibitora angiotenzinprevrashchaiushchego fermenta spiraprila pri khronicheskoĭ pochechnoĭ nedostatochnosti, gipertonii i diabeticheskoĭ nefropatii [The ACE inhibitor spirapril in chronic renal failure, hypertension and diabetic nephropathy]. Ter Arkh. 2000;72(10):78-82. Russian. PMID: 11220886.
8: Kantola I, Terént A, Honkanen T, Järveläinen V, Ekman K, Kataja M. Efficacy and safety of spirapril, a new ace-inhibitor, in elderly hypertensive patients. Eur J Clin Pharmacol. 1996;50(3):155-9. doi: 10.1007/s002280050085. PMID: 8737752.
9: Nørgaard K, Jensen T, Christensen P, Feldt-Rasmussen B. A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension. Blood Press. 1993 Dec;2(4):301-8. doi: 10.3109/08037059309077172. PMID: 8173700.
10: Schürer M, Erb K, Junge K, Schäfer HF, Schulz HU, Amschler S, Krupp S, Hermann R. Drug interaction of spirapril hydrochloride monohydrate and hydrochlorothiazide. A clinical study to compare the pharmacokinetics after administration of spirapril hydrochloride monohydrate tablets, hydrochlorothiazide tablets and fixed combination bi-layer tablets. Arzneimittelforschung. 2003;53(6):414-9. doi: 10.1055/s-0031-1297129. PMID: 12872612.
